Chief Executive Officer's Statement

Introduction

G&H delivered a strong performance in the second half of the year underpinned by solid demand for our Life Sciences and A&D products and also reflecting the significant operational improvements that were made across the Group following a challenging first half due to reduced demand in our industrial and medical laser markets. 

The growth in revenue in the second half and the continued strong order intake reflect multi-year programme wins and the positive structural trends evident in many of our end markets, albeit with the recovery of the semiconductor market still not evident and now expected in the second half of FY2025. This has been complemented by a number of new customer wins and incremental business opportunities with existing customers. Our teams across the Group have executed exceptionally well in a challenging environment, given the significant supply chain and cost headwinds, to deliver a robust trading performance in the second half of the year in line with expectations that supports improved profit growth in FY2025. Having now completed my second full year with G&H, I am pleased with the continued foundational progress that has been made across the business through the collective hard work of the workforce which is now being harnessed more effectively through a more focused and fully deployed strategy to deliver sustainable margin growth for the Group.

A significant cornerstone of our strategy is for the Group to become a more customer focused business and to deliver an exceptional customer experience when doing business with G&H. I am pleased to see how this is being embraced across the whole Company and the progress that is being made through disciplined focus on internal and external customer delight. Following our 2024 Customer Satisfaction Survey, it was encouraging to see the improvements in all the key metrics that resulted in an increased Net Promoter Score for G&H up to 42 from the previous score of 10 in 2023, demonstrating that our customers are already starting to recognise the changes we have made and continue to make with this key strategic priority for the Company.

I am proud that G&H's products and technology are playing a part in building a better more sustainable world. Many of our products contribute directly to the reduction of energy consumption and the more efficient use of materials. In our own facilities we are also making great strides in reducing our impact on the environment. In FY2024 we achieved a 14.3% reduction in our emissions intensity measure as we work towards our goal of being net neutral on our Scope 1 and 2 emissions by 2035.

Business Performance

After the disappointing performance reported in the first half, the Group delivered strong trading momentum during the second half of the year with revenue up 15% enabled by the focused operational improvements and capability investment made over the last year (FY2023: 5% increase). For the full financial year 2024, G&H achieved revenue from continuing operations of £136.0m which was broadly flat on the previous year (FY2023: £135.0m), or on an organic, constant currency basis with the full year benefits of Artemis and GS Optics excluded, revenues were down 3.0%. Adjusted profit before tax from continuing operations was £8.1m, a reduction of 21.6% over last year (FY2023: £10.3m).

During FY2024 we saw continued solid levels of customer demand albeit at more normalised levels resulting in the order book stabilising at £104.5m at year end (FY2023: £115.3m after adjusting for the divestment of the EM4 business). On an organic constant currency basis, the order book declined by 5% during FY2024, partially due to a further £1.4m reduction in the Group's past due backlog and from the timing of orders for our medical diagnostic instruments. Our order book for medical laser devices has also declined but we are now starting to see evidence of some recovery from this market. In our industrial markets, whilst the destocking patterns we saw in the first half of the year now appear to be behind us, we have not yet seen sustained recovery in the industrial laser market. Offsetting these declines our A&D order book has grown strongly in the financial year thanks to increased demand from both our commercial and defence customers assisted by the enhanced value proposition we are able to offer. Our teams in the UK and US are focused on converting a healthy pipeline of new A&D prospects and there has been further extension of the order book following the year end.

Strategy

G&H is a business with outstanding products, enormous technical capability and highly talented people and following the launch of our new strategy in the summer of 2023 we are now starting to see the foundational benefits   from greater focus on operational execution, customer experience, employee engagement and better prioritisation of our R&D technology and investment.

Our new strategy continues to refocus the whole business on delivering sustainable margin growth and transforming G&H to become an 'innovative customer focused technology company' delivered responsibly by making a 'better world with photonics'. We are making good progress to ensure that G&H becomes and remains the 'first choice' for all our stakeholders including our employees, our customers, our shareholders, our eco-system partners or the communities where we operate. We are offering a more differentiated performance through the four pillars of our strategy centred around, firstly, our people by establishing dynamic high-performance teams and a purpose-led culture; secondly, through self-help activities to deliver exceptional customer service and superior operational execution; thirdly, through value creation from our technology and photonics expertise; and, finally, by focused investment, both organic and inorganic, to accelerate accretive growth.

Acquisitions and Portfolio

The Group's new strategy has identified a path to mid-teen returns over the medium term that includes benefits from our 'portfolio' activities achieved through addressing non-performers in combination with pursuing 'speed to value' acquisitions. Following the two strategic acquisitions of GS Optics and Artemis Optical in the summer of 2023, we have made good progress with the integration of both of these businesses into the Group. These two acquisitions marked a significant milestone and alignment with G&H's strategic vision for growth through a greater focus on adding value through the transition from complex photonics components to a sub-system or full system solution by targeting two businesses that enhance our fuller photonics systems offering into Aerospace & Defence markets with Artemis in Plymouth UK and into the North American Life Sciences market through GS Optics in Rochester NY. We invested in both businesses during the year to establish enhanced capabilities at both facilities, most notably with the addition of a further coating chamber in Plymouth and the establishment of a new Life Sciences R&D hub and medical IVD device ISO13485 certified manufacturing centre in Rochester. Both acquisitions are proving to be an excellent fit in terms of our commitment to precision, innovation and customer focus, supporting the delivery of the Group's strategy.

Aligned to our strategy to review our portfolio to address non-performing or non-core parts of the Group, we concluded that the majority of products supplied by our EM4 facility in Boston were not sufficiently differentiated to generate the level of returns needed to support the Group's journey to mid-teens returns. In March 2024 G&H announced the divestment of EM4 to Luminar Technologies as the result of the carefully considered and ongoing review of our A&D product portfolio. This disposal supported the Group's consolidation of our A&D activities into areas where we can offer differentiated products to our customers and enable the Group to grow our optical systems business and maximise value creation from accretive optical systems solutions. At the same time prior to the sale, G&H successfully transferred out of EM4 to other G&H facilities technology for fibre fusing which is differentiated and is employed in the modules we supply into advanced photolithography equipment and some medical device applications.

Our Markets

Industrial revenues in FY2024 at £67.9m declined by 9.1% from the prior year due to the continued slowdown of the semiconductor market and protracted destocking in our Industrial markets. Despite these challenges in the year, volumes of our fibre optic modules and assemblies used in both next generation advanced lithography systems and subsea data networks remained robust with growth in the second half as new programmes started to migrate to volume production and demand picked up our long-standing hi-reliability fibre couplers. Revenue from our industrial laser customers were weaker than the prior year remaining broadly flat through FY2024 and whilst some early signs of a pick-up in demand were evident towards the end of the year, we continue to watch developments closely and work with our key partners in this space to assess changes to demand visibility. Any sustained recovery from our broader industrial laser and semiconductor markets is now not expected until the second half of the coming calendar year.

A&D revenue growth in the year was 26.0% and on an organic constant currency basis grew by 10.3% compared with the prior year. Volumes in our Aerospace & Defence markets grew significantly as a result of improved productive capacity at several of our sites and as a number of new projects move into production phase, along with the early commercial synergy benefits of the Artemis Optical acquisition starting to be realised especially around advance laser protection capabilities that we can now offer alongside our superior optical systems products. Our imaging and sighting systems business for armoured vehicles and UAVs continues to progress well with a number of multi-year new programme wins during FY2024 where the conflict in Ukraine is fuelling increased demand and greater urgency of supply. This was particular evident from the second half revenue growth from deliveries of precision optics and advanced sighting systems into both air and land military platform programmes. In the commercial aerospace market demand for our ring laser gyro components was strong and the Group is now benefiting from the additional capacity we have added to meet this increased demand.

The Life Sciences business performed well overall with revenues up 1.3% on a constant currency basis and we saw continued growth in demand for our medical diagnostic products. For example, a cancer care product initially designed by our customer and then productionised by our engineering team migrated through regulatory approvals and into production during the year and we expect to see further growth from this product platform in FY2025 and beyond. Our Life Sciences R&D team remained fully engaged in supporting customers with the design and regulatory accreditations of their next generation instruments which are expected to convert to production revenue for the Group in the coming years. We have also received positive and encouraging levels of customer interest and initial orders for our new North American Life Sciences Centre of Excellence in Rochester NY which was established during the year and has already received ISO13484 certification for the manufacture of medical devices. We expect this facility to be a key part of our growth strategy for our Life Sciences business in the future. However, the other part of our Life Sciences business focused on the design and manufacture of products into the medical laser market had a challenging year. Despite some recovery in demand in the second half, we continued to see a significant slowdown in the demand for our medical lasers mainly due to extended destocking from some of our customers as well as the impact of competition in certain product segments from lower cost Chinese products.  

Following the transfer of our acousto-optic products from our Ilminster facility to our Asian contract manufacturing partner, we have now qualified and successfully transferred the manufacture of a significant portion of our hi-reliability fibre coupler business to that same partner. During FY2024 we were able to accelerate the preparations for the transfer of further fibre optics and other products, where technological sovereignty is not a differentiator, building upon a proven model that has now been established with our selected contract manufacturing partners.

We have continued to invest in our technology roadmaps albeit with a greater focus following the recent strategic review and our R&D teams are working closely with many of our customers on the accelerated development of their next generation products. Total investment on product development activities increased to £7.8 million in FY2024 (FY2023: £7.4m). During the year, the Group reduced net capital expenditure to £5.2 million compared with £7.3 million in the previous year aligned to our strategic objectives. Notable spend in the period was focused on the integration of the new acquisitions, Artemis and GS Optics and establishing our Life Sciences innovation hub and centre of excellence in Rochester NY. Carefully selected capital investment was also made in our optical systems and precision optics business to address bottlenecks and meet increased customer demand alongside the operational efficiency activities underway at these sites. 

The Group retained high levels of inventory during FY2024 that are still above pre-pandemic levels, however, through greater focus and improved supply chain and inventory management disciplines being implemented across the Company there was a pleasing reduction during the period and this trend is expected to continue into FY2025.  

This combined with strong collections of receivables and the funds from the sale of the EM4 business resulted in net debt excluding lease liabilities reducing to £16.0m from £20.9m. Our leverage as measured for our banking covenant stands at 0.9x (2023 1.1x), which along with available committed and uncommitted bank facilities of $39.6 million places G&H in a strong position to pursue our strategic goals.

Research and Development (R&D)

G&H continues to work closely within the global photonics ecosystem and with a number of key partners to develop their next generation products. During FY2024 we introduced 48 new products (FY2023: 57) and delivered £25.3 million of revenue (FY2023: £26.1 million) from new products. Following our strategic review, we continue to refocus and prioritise our global R&D efforts and investment behind the following seven vital few areas:

1.     Expansion of AO technologies into Semiconductor market and EUV eco-system.

2.     New medical laser technologies and applications focused on moving up value chain from component to sub assembly and full systems.

3.     Advanced fibre optics technology and systems supporting submarine networks.

4.     Imaging and sighting systems, especially focused on the A&D market, for periscopes, sights and other optical sub-systems.

5.     Precision optics added value and advanced coatings and laser protection filtering capabilities.

6.     Moving up the value chain in Fibre-Optics with a focus on sensing, modules, LiDAR.

7.     Medical diagnostics and bio-photonics IVD solutions with strategic focus on expanding our offering into the US Life Sciences market.

During FY2024 technology roadmaps have been developed to refocus R&D activities around these seven 'vital few' areas for the Group to drive 'value creation'. There has been investment to strengthen acoustic-optic engineering and product line team with the appointment of additional technical and product development capability. In the Fibre optics business unit we saw strong progress with the customer-led development of next generation systems for semi fab, submarine network and medical diagnostics. The precision optics and optical systems technology teams have been enhanced by the advanced coatings engineering team that joined with the acquisitions of Artemis and disciplined refocus of our highly talented engineering team in St Asaph is already delivering better outcomes. The successful launch of our new US Centre of Excellence in Rochester NY long with the new engineering talent that has joined the Group in this team during FY2024 is promising for the future. These R&D projects are expected to contribute more than £50m of incremental margin accretive revenue over the plan period.

Corporate Responsibility and Sustainability

The Board is accountable to its shareholders and is committed to the highest standards of corporate governance. To this end the Group has adopted the UK Corporate Governance Code (2018). In order to ensure the Group is meeting the most up to date standards, regular reviews of policy are held by the relevant committees of the Board of Directors. During the year the Board undertook a self-assessment to identify opportunities for improvement and incorporate a greater focus on ESG. Susan Searle, who joined the Board in FY2023 with a wealth of experience in many of the markets in which we operate and particularly sustainability matters, has Chaired the newly introduced Sustainability Committee which is already providing greater clarity and alignment to our activities in this area.

G&H is committed to creating a safe, engaging, diverse and inclusive place to work for the Group's employees and all stakeholders. We continue to establish a culture that proactively works towards reducing harm and promotes equality, diversity and inclusion across the company. The Group remains focused on providing equal employment opportunities for all and aims to improve diversity at all levels of the organisation. Our recruitment partners have been instructed to ensure that they include women in all shortlist applications, and we are actively engaged with encouraging International Women in Engineering.

G&H is committed to conducting our business in an environmentally responsible and sustainable manner. We are investing in order to generate our electricity in a sustainable manner and to reduce our overall energy usage. Each of our sites has an energy reduction plan that it is working to. In the year we reduced our Scope 1 and 2 carbon emissions by 19.2%, another major step forward in achieving our target of being net neutral on this measure by 2035. It was particularly encouraging to see our facility in Torquay become the first Scope 1 and 2 net neutral zero site across the Group, leading the way for other to follow in the future. We were also pleased to see a further two sites, Ashford and Keene (FY2024) join Ilminster, Torquay (FY2023) and Fremont sites with certification to the environmental ISO14001 standard. This now means that 50% of the Group's global footprint is covered by this environmental accreditation and 70% of our employees. This was a core commitment when we launched our new strategy in FY2023 and we are making good progress to achieve the deployed road map to roll this same initiative out across all our manufacturing sites by 2027. The Executive Directors and senior leadership team all have specific environmental management and carbon reduction goals in their remuneration schemes.

Outlook

During FY2024 the Group has made further positive progress in establishing strong foundations to deliver our strategic priorities and enhance mindshare with our customers many of whom are demonstrating a growing confidence in G&H. Despite the challenges the Group faced during the year through the reduced demand in our industrial and medical laser markets persisting longer than expected which resulted in a material impact to trading in the first half, G&H is well positioned to benefit from recovering demand levels in these markets now expected in the second half of 2025. In the second half, we delivered the expected top line growth for the Group through the improvements in operational execution and a solid order book, which reflected a significant number of new customer wins, incremental business opportunities with existing customers and continuing market share gains. Our teams across the Group have performed exceptionally well in a year characterised by further significant change, ongoing supply chain issues, destocking and continued cost inflation.  I would like to extend my thanks to all our employees for their hard work and highlight the positive way the whole organisation has embraced the transformational changes underway across the Company.

G&H is well-aligned with the prevailing global mega trends, many underpinned by the next frontier of photonics, which is driving demand from high-growth markets. The current surge in demand in the A&D markets is expected to last for a number of years and G&H is positioned particularly well with our existing capabilities and the addition of enhancing technology in this area through recent acquisitions.

Whilst we do not expect to see our industrial laser and semiconductor markets return to growth until next year, we are seeing strong demand for our advanced optical systems capabilities from the defence sector and there are significant new business opportunities that we are working hard to secure. G&H continues to make progress on delivering the self-help, technology and portfolio activities that underpin our strategic plan. We saw further improvement with on time delivery performance in FY2024 and customer feedback is now trending in a positive direction. The Group is now better positioned to benefit from the anticipated recovery in our end markets next year thanks to the disciplined implementation of our strategy. This has been further underlined by the recent successful acquisition of Phoenix Optical at the beginning of the new financial year in October. Phoenix is an excellent fit within G&H and the initial feedback from our combined customers has been particularly encouraging.

Despite this positive overall outlook for the Group, we remain cautious about some supply chain and commercial headwinds in the near term.  The labour markets for talent in both the UK and US remain competitive leading to some supply side challenges that continue to frustrate the recruitment of the required talent, especially in engineering and technical positions. Global supply chain constraints, although better than in the recent past, continue along with an inflationary environment for wages, raw materials and energy all require diligent attention and agility. Whilst price increases have been passed onto customers in FY2024 to address most of these cost increases, cost inflation continues to impact the business and the ability to fully offset all cost base inflation through pricing actions is becoming more difficult in certain areas.

While mindful of the persistent macroeconomic and geopolitical uncertainties that exist, G&H remains well positioned for growth with a robust pipeline across all our end markets. The business will invest to ensure G&H can capitalise on the accelerating deployment of photonics technologies into continuously expanding areas of the industrial, life sciences, A&D markets underpinning the future growth potential of the Group. I am confident we will build on the foundational progress made over the last year, supported and clearly directed from G&H's fully deployed strategy, to become a more resilient and agile higher margin business over the coming years for all our stakeholders and realise our clear vision of 'A Better World with Photonics'.

Charlie Peppiatt

Chief Executive Officer

3 December 2024

Operations Review

Industrial

Revenue                                         £67.9m (FY2023: £74.7m)

Adjusted Operating Profit            £7.8m (FY2023: £10.6m)

Adjusted Operating Margin         11.5% (FY2023: 14.2%)

Operating Profit                            £7.2m (FY2023: £9.4m)

Percentage of Group Revenue   50.0% (FY2023: 55.3%)

Market Drivers

·    Cloud computing, artificial intelligence, hyper connectivity and automation all drive demand for semiconductors.

·    Political uncertainties driving the re-shoring of the manufacture of key components such as semiconductors.

·    Next generation products such as extreme ultra violet (EUV) lithography lasers for nanoelectronics and new design germanium modulators.

·    New flexible materials being used for the next generation personal data devices require new forms of industrial laser cutting and marking machines.

·    Increasing transfer of data internationally for both business and personal use drives the demand for subsea data cables.

·    Accelerating investment in wind generated clean energy particular in the US. Our 'laser engine' sensing technology improves the efficiency of wind turbines.

·    Remote border and infrastructure asset protection receiving increasing investment driving demand for our sensing products.

Our products enable

·    Industrial lasers for materials processing applications. G&H supplies Q-switches and other acousto-optic, electro-optic and fibre optic products.

·    Semiconductor for lithography and test and measurement applications.

·    Metrology for laser-based, high-precision, non-contact measurement systems.

·    Optical communications specifically for high reliability and high-performance applications.

·    Remote sensing for applications including asset protection, perimeter security, strain, temperature and pressure sensing.

·    Scientific research the largest proportion being nuclear fusion research and energy - laser technology is being used to recreate the conditions found in the core of the sun.

Our strategy in action

During the year we continued to deliver on our strategic objective of transferring more of our stable production to our low cost region contract manufacturing partner. Building upon the transfer of some of our acousto-optic products during FY2024, we supported our partner to increase the volume of hi-reliability fused couplers they make for us. This included securing important customer qualification of their facility for the manufacture of these very sophisticated devices. We supported their ramp up by transferring further production rigs that are used for the manufacturing process to them. As a result all of the Group's traditional hi-reliability fibre couplers are now built by our two contract manufacturing partners as we have migrated our own in-house production teams on to the build of more complex fibre optic sub-assemblies and modules. This represents a significant pivot for the production team in our Torquay facility, but one they have embraced with significant skill and dedication.

Our products used in the manufacture of the most advanced micro chips using EUV projection are now in steady state production. This represents a considerable success of converting one element of our technology roadmap in to a strong and recurring revenue stream.

Another example of this was our development of an advanced fibre optic amplifier module used in an important new subsea data cable network. During FY2024 we secured the customer's contract, completed our design activities and achieved the deliveries of production units to our customer. This is another pleasing example of us using our technology roadmap to move up this specific value chain from providing this market with hi-reliability fused couplers integrated by others in to higher level assemblies in to bringing that activity in to G&H helping with

the growth of both the Group's revenue and profitability.

Our fibre optic technology is also used to support the growth of the world's renewable energy generation market. In this sub market we were pleased to see another product from our technology roadmap migrate in to production. We are providing a complex fibre optic assembly that is integrated with energy generating wind turbines to assist with their safe operation and efficient generation of energy.

Despite this pleasing progress on the delivery of our strategic objectives we were impacted by the general industrial market slow down, especially in the first half of the financial year when a number of our customers found themselves in an overstocked position and reduced their orders in order to correct their inventory holdings. Volumes recovered to some extent in the second half but nevertheless our revenue in this segment declined by 9.7% on an organic, constant currency basis.

Our revenue into both the Industrial laser and more established areas of the semiconductor manufacturing environments both declined sharply. Our growing deliveries into the more advanced semiconductor manufacturing systems which increased by around 50% were not enough to offset these other sub market declines.

Deliveries of our sensing products also declined. Revenue in this sub-market is prone to fluctuation in our end customers' infrastructure build out programmes and FY2024 was a disappointing year in this regard.

Subsea data market revenues grew well driven by additional demand from one of our large, long-standing customers in the subsea data cable laying market. This was thanks to additional end market demand but it was also pleasing to be able to generate first revenue from a new customer we have secured for whom we are providing an advanced amplifier unit that is incorporated into their subsea data cable network.

Strategic priorities for FY2025

·    We are adding further resources to our development teams focused on our acousto- and electro- optic products which form the majority of our product offerings into the Industrial market. We have good connections with our customers' development teams and expect this close working to result in the Group securing new programme positions on our customers' next generation industrial laser and semiconductor manufacturing equipment.

·    We will bring new products to the market and ensure that we remain at the cutting edge of technology in this growing market. During FY2024 G&H introduced 23 new products in Industrials generating £11.7m of revenue.

·    We have identified further products that we will transfer to our low-cost contract manufacturing partners to support our margin expansion and to extend the lives of these products. This will support us offering our customers additional capacity and shorter lead times. In some cases we have also identified the opportunity for margin expansion from substituting some of our existing supplier for our low cost region contract manufacturing partners.

·    We will focus on niche markets where the quality and reliability of G&H's product differentiate us from the competition in particular those that require reliable performance in harsh and demanding environments.

·    Through both cross sharing of experiences between our sites and focused kaizen events our operations team will focus on improving the efficiency of our factories, increasing our production yields, eliminating waste and further rationalising our inventory holdings. 

Aerospace & Defence

Revenue                                                    £34.5m (FY2023: £27.3m)

Adjusted Operating Loss                        £(1.2)m (FY2023: £(1.8m))

Adjusted Operating Margin                     (3.5%) (FY2023: (6.8%))

Operating Loss                                         £(1.5)m (FY2023 £(2.3m))

Percentage of Group Revenue               25.3% (FY2023: 20.2%)

Market Drivers

·       Global conflicts are driving further investment in both armoured vehicles and unmanned aerial vehicles (UAV) and measures to counter them.

·       Users require new features within their latest optical systems that integrate electronics and optics in single more complex packages.

·       Optics used in the defence arena increasingly require complex coatings, for which G&H is a leading supplier.

·       Photonic components and systems offer size, weight, power and reliability benefits for multiple A&D sub sectors.

·       IR optical arrays are used for targeting, range finding, navigation and surveillance capabilities for both UAV and counter measures.

·       These same capabilities are needed in the operation of remotely controlled and autonomous A&D systems for land, sea and air.

·       Space satellite communication systems are migrating from traditional radio frequency to laser-based systems. G&H's laser amplifier technology sits at the heart of these systems.

·       Directed energy systems have already been deployed on to naval platforms as part of their integrated defence systems. Significant investment is being made by Western governments in more powerful laser systems for other applications within and beyond naval warfare.

Our products enable

·       Target designation and range finding used on both land-based and airborne systems.

·       Guidance and navigation components for ring laser gyroscope and fibre optic gyroscope inertial navigation systems.

·       Countermeasures for ground-based systems and airborne platforms.

·       Space photonics G&H is leveraging its heritage of ultra-high reliability components for both space and very high altitude unmanned aerial vehicle applications in order to address the growing market for laser-based space communications.

·       Periscopes and sighting systems for land based armoured fighting vehicles.

·       Opto-mechanical subsystems for unmanned aerial and ground vehicles.

·       Directed energy systems for military platform and infrastructure defence applications.

·       Advanced optical coatings for both laser protection and platform stealth

·       Acrylic optics for low weight, less expensive optics as required for solider, body worn system such as night vision goggles and rifle scopes.

Our strategy in action

During FY2024 we made good progress on the development of the advanced periscope systems that we will deliver into the UK Army's Challenger 3 MBT upgrade programme. We shipped first prototypes to the prime contractor and our systems were integrated in to the vehicle for successful live firing trials. We expect to complete development activities in the first half of the coming financial year.

The same core technology is being used for a periscope system that we are providing to an eastern European NATO country for a new amphibious armoured vehicle programme. We will commence delivery of production units in the coming few months. We expect to secure further orders from this programme as the end customers places orders for the full programme quantities. 

The thin film coating capability that our Artemis business, which we acquired last year, provides is able to offer protection against the harshest threats from lasers as they are now being deployed on the modern battlefield. This has led to Artemis being invited to tender for the emerging requirements of western militaries, and in turn Artemis are able to cross sell other precision optic products and capabilities from other G&H sites.

One of the priorities set out in our refreshed strategy was to review our portfolio of products and to assess whether they were all sufficiently differentiated to allow us to command acceptable returns for the Group. In the first half of the year we concluded that the majority of the products offered by our EM4 business in Boston did not meet that threshold and it was, therefore, decided that we would divest the business. That divestment was completed in March 2024. Before completing the sale we transferred a fibre fusing technology from that business and moved it to our Torquay facility as it is deployed in some of the products we supply in to the world's most advanced photolithography machines and its retention was therefore very important for the Group. Shortly before its sale, the EM4 business saw some of its contracts cancelled by the end customer further supporting our decision to divest  the business.

Our revenues in our A&D segment grew by 10.3% on an organic constant currency basis. Demand for our super polished optical components used in ring laser gyroscopes is very strong and due to the investments we have made in our team at Moorpark where those components are manufactured revenue grew. However, our progress on improving our production yields was slower than planned. Our precision optics are prone to damage as they complete the production process and with a large number of new, less experienced operators joining our team costs associated with poor quality increased. Reversing this trend will be a priority for us for the new financial year.

Our engineering teams continue to be active in the field of laser-based space communications. Building upon work previously completed with our satellite partners we are now developing more powerful laser amplifiers that will enable transfer of greater volumes of data. Our work in this area is an important element of our more focused and accelerated technology development programme. We believe we are well positioned to benefit as the laser-based space communication develops more fully.

We are also contracted by a number of prime contractors on Directed Energy Systems. G&H's expertise in coating the large optics that are positioned at the heart of these systems means that we are well positioned to secure recurring revenue once these programmes transition to volume production. There is a clear trend towards greater reliance by western militaries upon directed energy systems within their overall suite of defensive capabilities.

Strategic priorities for FY2025

·        We will complete the development of our advanced periscope systems for the Challenger upgrade programme and exploit the core technologies that we have developed to address their customers' needs.

·        We will use the access that Artemis' unique thin film coating capability gives us to leverage the sale of precision optic products and capabilities from across the G&H Group.

·        We will implement targeted improvement programmes to address the poor yields and high scrap costs that we have experiences in some of our sites supplying the A&D segment in FY2024.

·        We will introduce a greater number of new products, especially those with a high technical content. During FY2024 G&H introduced 19 new products and generated £6.6m of revenue from new products that addressed the A&D market including space satellite laser-based communication systems, new sighting systems and IR lens assemblies for UAVs.

·        We will use our expanding operational footprint arising from our acquisition of the Phoenix business to optimise the location of manufactures of our growing order book in the A&D segment.

·        We will work on the swift integration of the Phoenix business with the rest of the G&H Group to enable us to deploy the resources of the G&H Group to sell the business' products worldwide.

Life Sciences

Revenue                                           £33.6m (FY2023: £33.0m)

Adjusted Operating Profit              £4.6m (FY2023: £4.3m)

Adjusted Operating Margin           13.8% (FY2023: 13.1%)

Operating Profit                              £3.9m (FY2023: £3.3m)

Percentage of Group Revenue      24.7% (FY2023: 24.4%)

Market Drivers

·    A growing aging population generating demand for a shift towards early diagnosis rather than later, more serious treatment of undetected conditions.

·    A trend towards more point of care and personalised medicine driving demand for simple, volume diagnostic products.

·    Growing demand for laser enabled aesthetic procedures especially from Asia, and in the West for tattoo removal.

·    A growing middle class influenced by social media eager to access laser enabled cosmetic and aesthetic procedures

·    New applications for optical coherence technologies beyond the traditional areas of eye examination and treatment.

·    Greater use of cheap, disposable plastic optics in life science instruments to avoid infection.

Our products enable

·    Medical diagnostic instruments: G&H has a range of capabilities including full product development, design, manufacturing, certification and after sale service for the commercialisation of high-quality medical diagnostic, in vitro diagnostic (IVD) devices, precision analytical, electro-mechanical and laboratory instruments.

·    Advanced polymer optics are playing an increasing part in medical optics due to the cost and weight benefits as well as the need for disposable systems to avoid infection.

·    Optical coherence tomography (OCT) primarily used in retinal imaging for the diagnosis of glaucoma and macular degeneration, but also now used in the detection of cardiovascular disease and cancer diagnostics.

·    Laser surgery used in a wide range of applications including prostate surgery, scar correction, cataract surgery, freckle, mole and tattoo removal as well as wrinkle reduction and teeth whitening.

·    Microscopy: Modern, laser-based techniques are revolutionising the field of microscopy.

Our strategy in action

Following the acquisition of the GS Optics in June 2023, we have worked quickly to convert space in their Rochester facility into a Life Sciences design and production centre replicating the capabilities that we have at our Ashford site in this North American centre of excellence. We have achieved ISO 13485 accreditation for the new facility and secured our first R&D contract for the team there. This represents an important step in our strategy to access the very large North American medical diagnostic market with US based resources.

The integration of GS Optics into G&H is now complete and our business development teams are implementing targeted campaigns to offer GS Optics' polymer capabilities to the Group's existing Life Sciences customers to address their needs for disposable healthcare optics and other components providing a one stop shop solution for their diagnostic device requirements. These cross-selling campaigns are expected to support GS Optics' growth in FY2025.

Our ITL business in Ashford is working with customers on the development and accreditation of their next generation medical instruments. Wherever these developments require optical components, the ITL business is able to cross sell products and capabilities from other parts of the G&H Group ensuring we capture a larger share of our customers' total spend.

Due to improvements made in our operations and supply chain processes at our Ashford site we were able to respond quickly to growing demand from some of our customers for additional volumes driven in turn by the success of their product launches with their end customers. Despite growing volumes, the site was able to reduce its inventory holding given greater confidence in our supply to delivery on time and our deployment of improved forecasting and material planning tools and processes at the site.

Working with our customers, we have identified some opportunities for the outsourcing of certain components and modules that form part of those medical diagnostic instruments to our low-cost region suppliers. Initial samples have been received and in the coming year we will progress these transfers to access the opportunities for margin accretion and additional surge capacity that these transfers offer, working closely with our clients through this process.

In our medical laser market, confronted by growing competition in the area of less complex medical laser components we are assessing our options for reducing our cost of manufacturing potentially using our low cost region suppliers as well as assessing in which parts of our current portfolio we can continue to offer differentiated products.

Our Life Sciences revenue grew by 1.3% on an organic constant currency basis in the year to 30 September 2024, compared with the prior year. Demand for our medical diagnostic instruments grew strongly offsetting the decline we saw from our medical lasers markets which was significant especially in the first half of the year and the medical laser OEM corrected their inflated inventory holding. We started to see this position recover in the fourth quarter.

Strategic priorities for FY2025

·    We will complete the resourcing of our expanded sales and business development team focused on securing new business for our Life Sciences business, with a specific focus on production orders for our North American Life Sciences centre of excellence.

·    This team will also focus on opportunities to cross sell GS Optics polymer optics in to our existing Life Sciences customer base.

·    We will complete the transfer of production of some of the components and modules used in our medical diagnostic instrument to our low cost region supply chain to support margin accretion and a surge build capability.

·    We will work with our OEM Life Sciences customers to finalise the development and accreditation of their next generation medical devices and secure the follow-on production revenue from their instrument build.

·    We will complete our assessment of our product range currently supplying the medical laser market in the face of growing low cost Asian competition.

·    We will continue to invest in R&D projects in close collaboration with our customers. During FY2024 G&H introduced 6 new products and generated £7.0m of revenue from products that address its life Sciences market, especially in the medical instrumentation market.